GVR Report cover Clinical Trials Support Services Market Size, Share & Trends Report

Clinical Trials Support Services Market Size, Share & Trends Analysis Report By Service (Clinical Trial Site Management, Patient Recruitment Management), By Phase, By Sponsor, By Region, And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-4-68039-475-9
  • Number of Pages: 100
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2020
  • Industry: Healthcare

Report Overview

The global clinical trials support services market was estimated at USD 19.4 billion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 7.5% from 2022 to 2030. The global market is projected to expand rapidly due to the rising demand for trials in emerging economies, rising R&D investment, and an increasing number of contract research organizations (CROs). The pharmaceutical firms’ (R&D) venture has been steadily increasing every year, largely due to patent expirations. An ordinary patent terminates after 20 years; in the pharmaceutical area, there is an arrangement that provides for the entry of a generic version of the medication into the market following a time of 10 years. Thus, firms are boosting their R&D interests to speed the advancement of drugs, subsequently extending the whole market. 

U.S. clinical trials support services market size, by phase, 2020 - 2030 (USD billion)

Clinical trials support services are quite useful in the event of a drug, assay design, and clinical testing. It also covers tasks such as strengthening clinical test locations, securing and storing research medicines, drug dosage calculation, and kit handling. Preclinical groundwork and research are provided by clinical test support services, which include clinical test site assistance, obtaining and storing study drugs, blinding of study drugs, patient recruiting, coordination, and reconciliation of returned medications.

The clinical trial sector underwent significant changes in 2021. With the introduction of COVID-19 vaccines, numerous clinical trials that had been halted due to the pandemic were re-initiated. In the first quarter of 2021, around 44% more clinical trials commenced compared to the first quarter of 2020. Although in-person clinical trials were once again viable, adoption of new technologies remained high, with 74% of sponsors adopting remote monitoring and 77% of sites using eRegulatory software.

Many software tools for data management are referred to as “Clinical Data Management” (CDM) systems. Multicentric trials require CDM systems to handle massive volumes of data. The majority of CDM systems utilized by pharmaceutical companies are commercial, but there are a few free-source tools accessible as well. Oracle Clinical, Clintrial, Oracle Clinical, Macro, RAVE, and eClinical Suite are common CDM tools. Maintaining an audit record of data management actions is important in regulatory submission studies. These CDM tools help ensure the audit trail and manage discrepancies. The CDM activities include data collection, CRF tracking, CRF annotation, database design, data entry, medical coding, data validation, discrepancy management, and database lock.

Service Insights

Clinical trial site management includes site recruitment, retention, and monitoring. It accounted for the largest market share of 43.9% in 2021. The rising number of clinical trials, high prevalence of chronic diseases, and the increase in the number of CROs offering services are key factors anticipated to drive the market in the coming years. Site monitoring accounts for 9% to 14%, and site retention accounts for 9% to 16%. Thus, clinical trial site management accounts for around 29% to 59% of the entire cost of a trial.

Proper site management by the sponsor and/or CRO is crucial for trial execution and trial success. A sufficient degree of site administration and monitoring enables facilities to efficiently recruit, treat, and retain subjects while maintaining regulatory compliance, protocol adherence, subject rights protection, subject safety, and overall management of screened and recruited subjects.

Phase Insights

The phase III segment dominated the market with the largest share of 53.9% in 2021. This growth can be attributed to the fact that phase III clinical trials are the most expensive ones and involve a significant number of subjects. The failure rate in this phase is the highest due to the sample size, and the study design requires complex dosing at an optimum level. The loss associated with failure is both human & financial, and the majority of the failures occur due to noncompliance with safety & efficacy standards.

The phase I segment is anticipated to register the fastest CAGR during the forecast period. Clinical trial support services for phase I include sample collection management, early phase patient screening, data management, and assay redesign & others. The U.S., Europe, and China, followed by Canada & Australia, are thus recognized as crucial centers for registering and conducting substantial phase-I clinical trials. As a result, there is a significant market for clinical trial management services in these countries.

Sponsor Insights

The pharmaceutical & biopharmaceutical companies' sponsor segment dominated the market with the largest revenue share of over 70.1% in 2021. The segment is also anticipated to witness the fastest CAGR from 2021 to 2030. This can largely be attributed to the increasing R&D investments and introduction of new drugs, which have increased in the past two decades. In 2019, the pharmaceutical industry spent USD 83 billion on R&D.

Global clinical trials support services market share, by Sponsor, 2021 (%)

The medical device companies segment is anticipated to show lucrative growth during the forecast period. In the clinical research industry, medical device manufacturers are minor customers, and clinical research sites generally focus on the more profitable sectors of biotechnology, pharmaceuticals, and fundamental research. However, as the FDA places an increasing focus on excellent clinical procedures, device makers will interact with this complicated business on a far more regular basis.

Regional Insights

North America dominated the global market in 2021 with the largest share of 50.4%, as most of the pharmaceutical businesses located in the U.S. perform a majority of their business in this region. This market is likely to grow due to the high number of clinical trials being conducted in the region. Major R&D investments and government support for clinical trials are further promoting market growth. The presence of key CROs offering clinical trial support services and multinational pharmaceutical & biopharmaceutical companies making major investments in clinical research has contributed to market growth in North America.

Asia Pacific is anticipated to be the fastest-growing regional market during the forecast period. Factors driving the APAC market include a developing patient population, simplicity of administrative compliance, minimal expense of conducting studies, and the presence of a couple of top clinical organizations acting at sites.

Key Companies & Market Share Insights

Some of the market players operating in the clinical trials support services market are Charles River Laboratories Intl Inc., Eurofins Scientific SE, IQVIA, Syneos Health Inc., and Icon PLC. Market players are undertaking various strategic initiatives, such as the signing of new partnership agreements, collaborations, mergers & acquisitions, and geographic expansion, aiming to strengthen their services, thus providing a competitive advantage.

For instance, in April 2019, the WuXi AppTec acquired a clinical research services company, Pharmapace, Inc., to expand its Biometrics offerings in clinical research with data management, statistical programming, clinical data integration, biostatistics, and medical writing. Some prominent players in the global clinical trials support services market are:

  • Charles River Laboratories Inc.,

  • Eurofins Scientific SE

  • IQVIA, Syneos Health Inc.,

  • The Pharmaceutical Product Development LLC

  • Icon PLC

  • WuXi AppTec

  • LabCorp

  • Alcura

  • Parexel International.

  • Others 

Clinical Trials Support Services Market Report Scope

Report Attribute

Details

Market Size value in 2022

USD 20.8 billion

Revenue forecast in 2030

USD 37.1 billion

Growth Rate

CAGR of 7.5% from 2022 to 2030

Base year for estimation

2021

Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Service, Phase, Sponsor, Region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; UK; Germany; France; Italy; Spain; Japan; China; India; Australia; South Korea; Brazil; Mexico; Argentina; Colombia; Chile; South Africa; Saudi Arabia; UAE

Key companies profiled

Charles River Laboratories Inc.; Eurofins Scientific SE; IQVIA; Syneos Health Inc.; The Pharmaceutical Product Development LLC; Icon PLC; WuXi AppTec; LabCorp; Alcura; Parexel International.

Customization scope

Free report customization (equivalent to up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail of customized purchase options to meet your exact research needs. Explore purchase options

 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the clinical trials support services market report based on phase, service, sponsor, and region.

  • Service Outlook (Revenue, USD Million, 2018 - 2030)

    • Clinical Trial Site Management

    • Patient Recruitment Management

      • Patient recruitment & registry services

      • Patient retention

      • Others

    • Data Management

    • Administrative staff

    • IRB

    • Others

  • Phase (Revenue, USD Million, 2018 - 2030)

    • Phase I

    • Phase II

    • Phase III

    • Phase IV

  • Sponsor (Revenue, USD Million, 2018 - 2030)

    • Pharmaceutical & Biopharmaceutical

    • Medical Devices

    • Others

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Colombia

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

 

Frequently Asked Questions About This Report

pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon gvr sidebar D&B icon gvr sidebar

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.